{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:27:53Z","timestamp":1782624473654,"version":"3.54.5"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030062"],"award-info":[{"award-number":["82030062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113899","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:15:02Z","timestamp":1748546102000},"page":"113899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Anti-CD33 antibody enhances liposomal co-delivery of cytarabine and daunorubicin for targeted combination chemotherapy"],"prefix":"10.1016","volume":"384","author":[{"given":"Jinyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113899_bb0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.biomaterials.2018.04.027","article-title":"Combinational strategy for high-performance cancer chemotherapy","volume":"171","author":"Qin","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113899_bb0010","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.113899_bb0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-05-1147","article-title":"Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha","volume":"12","author":"Sacchi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113899_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2020.04.018","article-title":"Design principles of drug combinations for chemotherapy","volume":"323","author":"Wu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113899_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biomaterials.2016.04.027","article-title":"An overview of the effective combination therapies for the treatment of breast cancer","volume":"97","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113899_bb0030","first-page":"848","article-title":"The Antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice","volume":"26","author":"Kline","year":"1966","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113899_bb0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/mi.7.4.8","article-title":"Optimizing combination chemotherapy by controlling drug ratios","volume":"7","author":"Mayer","year":"2007","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jconrel.2025.113899_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113899_bb0045","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1002\/adfm.201603336","article-title":"Codelivery of a \u03c0\u2013\u03c0 stacked dual anticancer drug combination with Nanocarriers for overcoming multidrug resistance and tumor metastasis","volume":"26","author":"Wei","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113899_bb0050","doi-asserted-by":"crossref","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","author":"Bozic","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2025.113899_bb0055","doi-asserted-by":"crossref","first-page":"39127","DOI":"10.1021\/acsami.7b08218","article-title":"Programmed Nanococktail based on pH-responsive function switch for self-synergistic tumor-targeting therapy","volume":"9","author":"Li","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.113899_bb0060","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mabi.201500043","article-title":"Synergistically improved anti-tumor efficacy by Co-delivery doxorubicin and curcumin polymeric micelles","volume":"15","author":"Wang","year":"2015","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2025.113899_bb0065","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"Pomeroy","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2025.113899_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3892\/or.2024.8805","article-title":"Routes and molecular mechanisms of central nervous system involvement in acute myeloid leukemia (review)","volume":"52","author":"Chen","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2025.113899_bb0080","article-title":"Acute myeloid leukemia and the bone marrow niche\u2014take a closer look. Frontiers","volume":"8","author":"Behrmann","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.jconrel.2025.113899_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jconrel.2025.113899_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.jconrel.2025.113899_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.24095\/hpcdp.39.8\/9.04","article-title":"Release notice - Canadian Cancer Statistics 2019","volume":"39","year":"2019","journal-title":"Health Promot. Chronic Dis. Prev. Can."},{"key":"10.1016\/j.jconrel.2025.113899_bb0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.jconrel.2025.113899_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.JAA.0000995680.52352.b5","article-title":"Acute myeloid leukemia: current understanding and management","volume":"37","author":"Becker","year":"2024","journal-title":"JAAPA"},{"key":"10.1016\/j.jconrel.2025.113899_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2025.113899_bb0115","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113899_bb0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.beha.2018.09.006","article-title":"Is there a standard of care for relapsed AML?","volume":"31","author":"Medeiros","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2025.113899_bb0130","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/Cytarabine liposome: A review in acute myeloid Leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113899_bb0135","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations tend to improve therapeutically relevant selectivity","volume":"27","author":"Leh\u00e1r","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110429","article-title":"Novel agents for acute myeloid leukemia","volume":"10","author":"Luppi","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.113899_bb0150","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ccr3.3909","article-title":"CPX-351 (Vyxeos(\u00ae)) can cause severe rash in acute myeloid leukemia-A case report","volume":"9","author":"Urbantat","year":"2021","journal-title":"Clin. Case Reports"},{"key":"10.1016\/j.jconrel.2025.113899_bb0155","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0160","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.bbmt.2019.12.605","article-title":"Efficacy and safety of CPX-351 versus 7+3 in a phase 3 exploratory analysis in patients with high-risk\/secondary acute myeloid leukemia (sAML) with prior Hypomethylating agent (HMA) exposure who achieved remission","volume":"26","author":"Lin","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jconrel.2025.113899_bb0165","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/nl102184c","article-title":"Nanotechnology in drug delivery and tissue engineering: from discovery to applications","volume":"10","author":"Shi","year":"2010","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.113899_bb0170","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jconrel.2020.04.009","article-title":"\u03b1v\u03b23-targeted liposomal drug delivery system with attenuated immunogenicity enabled by linear pentapeptide for glioma therapy","volume":"322","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113899_bb0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.apsb.2020.07.024","article-title":"A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.113899_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40487-019-00108-x","article-title":"The time has come for targeted therapies for AML: lights and shadows","volume":"8","author":"Fiorentini","year":"2020","journal-title":"Oncology and therapy"},{"key":"10.1016\/j.jconrel.2025.113899_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2025.113899_bb0190","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113899_bb0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1208\/s12249-020-01867-x","article-title":"Contrastive studies of Cytarabine\/Daunorubicin dual-loaded liposomes prepared by pH gradient and cu(2+) gradient method","volume":"21","author":"Zhang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2025.113899_bb0200","doi-asserted-by":"crossref","first-page":"29977","DOI":"10.1021\/acsami.6b10146","article-title":"Liposome-based systemic glioma-targeted drug delivery enabled by all-d peptides","volume":"8","author":"Ying","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.113899_bb0205","first-page":"6761","article-title":"Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies","volume":"52","author":"Caron","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113899_bb0210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4161\/mabs.1.6.10185","article-title":"IgG2m4, an engineered antibody isotype with reduced fc function","volume":"1","author":"An","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2025.113899_bb0215","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1248\/bpb.b16-00462","article-title":"Topology of surface ligands on liposomes: characterization based on the terms, incorporation ratio, surface anchor density, and reaction yield","volume":"39","author":"Lee","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2025.113899_bb0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biomaterials.2018.03.025","article-title":"Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy","volume":"167","author":"Niu","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113899_bb0225","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2025.113899_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2025.113899_bb0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2025.113899_bb0240","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2025.113899_bb0245","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Ting-Chao","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2025.113899_bb0250","article-title":"Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals","volume":"30","author":"Wang","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113899_bb0255","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113899_bb0260","article-title":"Cardiotoxicity induced by antineoplastic drug Daunorubicin and its amelioration: A review of literature","volume":"3","author":"S, Z., and K, H.","year":"2019","journal-title":"Blood, Heart and Circulation"},{"key":"10.1016\/j.jconrel.2025.113899_bb0265","first-page":"21","article-title":"The effectiveness of three different 7 + 3 induction regimes in China: A retrospective analysis in adult patients with acute myeloid leukemia. Pak","volume":"37","author":"Lin","year":"2021","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.jconrel.2025.113899_bb0270","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","article-title":"Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin","volume":"391","author":"Dicko","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113899_bb0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/cpb.c13-00587","article-title":"Thermotropic phase behavior of hydrogenated soybean phosphatidylcholine\u2013cholesterol binary liposome membrane","volume":"62","author":"Kitayama","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2025.113899_bb0280","article-title":"PEGylation in pharmaceutical development: current status and emerging trends in macromolecular and immunotherapeutic drugs","volume":"16","author":"Santhanakrishnan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jconrel.2025.113899_bb0285","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1182\/blood-2023-177706","article-title":"Base edited HSPCs are shielded from targeted CD33 therapy but preserve CD33 expression","volume":"142","author":"Beerlage","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113899_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133214","article-title":"CD33 expression and Gentuzumab Ozogamicin in acute myeloid leukemia: two sides of the same coin","volume":"13","author":"Molica","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113899_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030677","article-title":"New approaches for the treatment of AML beyond the 7+3 regimen: current concepts and new approaches","volume":"16","author":"Roman Diaz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113899_bb0300","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2017-01-762419","article-title":"Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia","volume":"129","author":"Godwin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113899_bb0305","article-title":"Nanodrug delivery: strategies to circumvent nanoparticle trafficking by Kupffer cells in the liver","volume":"86","author":"Ezhilarasan","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0310","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic Veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0315","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00277-021-04482-3","article-title":"Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy","volume":"100","author":"Ballo","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0320","series-title":"P516: Cardiotoxicity of CPX-351 Vs 7+3 in Patients with Untreated High-Risk Acute Myeloid Leukemia","author":"Mitchell","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113899_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47293-4","article-title":"Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro","volume":"13","author":"Fortin","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113899_bb0330","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/imt.11.5","article-title":"Antibody-targeted nanoparticles for Cancer therapy","volume":"3","author":"Fay","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2025.113899_bb0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ddtec.2018.10.003","article-title":"Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy","volume":"30","author":"Johnston","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: An updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113899_bb0345","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113899_bb0350","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of Cancer nanomedicines\u2014lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.113899_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/EBC20150007","article-title":"Bioconjugation and stabilisation of biomolecules in biosensors","volume":"60","author":"Li\u00e9bana","year":"2016","journal-title":"Essays Biochem."},{"key":"10.1016\/j.jconrel.2025.113899_bb0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2016.11.010","article-title":"Site-selective orientated immobilization of antibodies and conjugates for immunodiagnostics development","volume":"116","author":"Shen","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.jconrel.2025.113899_bb0365","first-page":"43","article-title":"Bioconjugation with Maleimides: A useful tool for chemical biology. Chemistry \u2013 A","volume":"25","author":"Ravasco","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0370","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41557-018-0209-2","article-title":"Maleimide\u2013thiol adducts stabilized through stretching","volume":"11","author":"Huang","year":"2019","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2025.113899_bb0375","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/10717544.2022.2039807","article-title":"Development of applicable thiol-linked antibody\u2013drug conjugates with improved stability and therapeutic index","volume":"29","author":"Wang","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2025.113899_bb0380","doi-asserted-by":"crossref","first-page":"13859","DOI":"10.1038\/s41598-019-50424-5","article-title":"Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17\u03b2-estradiol","volume":"9","author":"Oliveira","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.113899_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113899_bb0390","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2025.113899_bb0395","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2016.06.012","article-title":"Nanomedicine of synergistic drug combinations for cancer therapy \u2013 strategies and perspectives","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113899_bb0400","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/adfm.201303222","article-title":"Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy","volume":"24","author":"Jiang","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113899_bb0405","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2025.113899_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124424","article-title":"Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma","volume":"661","author":"Cao","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113899_bb0415","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2015.10.021","article-title":"Co-delivery of chemotherapeutics and proteins for synergistic therapy","volume":"98","author":"He","year":"2016","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500519X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592500519X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:55:20Z","timestamp":1779512120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592500519X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":83,"alternative-id":["S016836592500519X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113899","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD33 antibody enhances liposomal co-delivery of cytarabine and daunorubicin for targeted combination chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113899"}}